LitCovid-sentences  

PMC:7396557 / 70217-80871 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T524 0-56 Sentence denotes Relevant Information on the Clinical Application of XBJI
T525 58-90 Sentence denotes Recommended Therapeutic Regimens
T526 91-214 Sentence denotes XBJI has been recommended in 20 therapeutic regimens of COVID-19 in China (see detailed information in Tables 1 and 2 ).
T527 216-235 Sentence denotes Ingredients of XBJI
T528 236-444 Sentence denotes Carthamus tinctorius L. (Honghua), Paeonia lactiflora Pall. (Chishao), Conioselinum anthriscoides ‘Chuanxiong’ (Chuanxiong), Salvia miltiorrhiza Bunge (Danshen), and Angelica sinensis (Oliv.) Diels (Danggui).
T529 445-512 Sentence denotes Basic information on XBJI is provided in the Supplementary Table .
T530 514-565 Sentence denotes Indications for the Treatment of COVID-19 With XBJI
T531 566-672 Sentence denotes XBJI is used for syndrome of blood-stasis and toxins in the progressive stage of COVID-19 (critical case).
T532 673-755 Sentence denotes Indicative symptoms are fever, dyspnea and tachypnea, palpitations, and dysphoria.
T533 756-933 Sentence denotes It could also be used for treatment of infection-induced systemic inflammatory response syndrome and multiple-organ dysfunction syndrome in the stage of impaired organ function.
T534 935-979 Sentence denotes Progress of Pharmacological Research on XBJI
T535 980-1141 Sentence denotes Modern pharmacological studies have shown that XBJI is anti-inflammatory, antioxidant, immune-regulatory, and protects against acute lung injury (see Table 3 ).
T536 1142-1434 Sentence denotes Tiantian Li et al. found that in mice with MRSA-induced sepsis, XBJI protected the infected mice by downregulating expression of inflammatory cytokines stimulated by Pam3CSK4, MAPK, PI3K (phosphatidylinositol 3 kinase)/Akt and other pathways, thus, inhibiting the inflammatory response (Li T.
T537 1435-1452 Sentence denotes T. et al., 2020).
T538 1453-1824 Sentence denotes Shuwen Zhang et al. and Xi Chen et al. found that XBJI significantly reduced TNF-α, IL-6, and IL-10 levels in mice with sepsis, prevented neutrophil infiltration of lung and kidney, modulated T helper cell (Th) 1/Th2, Th17, and Tregs balance, reduced inflammatory response, and improved survival rate in mice with infectious shock (Zhang et al., 2006; Chen et al., 2018).
T539 1825-2092 Sentence denotes Mingwei Liu et al. studied rats with paraquat-induced acute lung injury and discovered that XBJI could enhance immunity, reduce expression of inflammatory factors, and protect against acute lung injury by blocking p-38 MAPK and NF-κB p65 pathways, (Liu et al., 2014).
T540 2093-2433 Sentence denotes Research by Yin Teng et al. found that XBJI in combination with conventional treatment significantly reduced interleukin-1 (IL-1), IL-6, and TNF-α levels, improved CD4+/CD8+ T lymphocyte ratio and NK cell relative activity, reduced inflammatory response, and enhanced cellular immunity in patients with severe pneumonia (Teng et al., 2012).
T541 2434-2691 Sentence denotes Research by Hui Jin et al. showed that XBJI significantly improved the activity of superoxide dismutase (SOD), reduced reactive oxygen species (ROS) levels and protected against oxidative damage in mice under high-temperature stimulation (Jin et al., 2018).
T542 2692-2861 Sentence denotes Research by Luo Peng et al. showed that XBJI downregulated MDA levels, upregulated SOD levels, and alleviated LPS-induced acute lung injury in rats (Luo and Zhou, 2017).
T543 2862-3077 Sentence denotes In a rat model of oleic acid or LPS-induced acute lung injury, XBJI reduced TNF-α levels, alleviated pulmonary tissue edema and inflammatory cell infiltration, and protected against lung injury (Zhang et al., 2014).
T544 3078-3361 Sentence denotes Research by Yuexia Ma et al. showed that although XBJI had no direct antiviral effect in mice with H1N1 severe pneumonia; it alleviated lung injury and protected against death, which might be due to its regulation of inflammatory cytokine levels in the early stage (Ma et al., 2015).
T545 3363-3388 Sentence denotes Clinical Research on XBJI
T546 3389-3676 Sentence denotes Modern clinical studies have shown that XBJI in combination with conventional treatment has therapeutic effects in relevant diseases, such as MERS, human infection with H7N9 avian influenza, CAP, severe pneumonia, systemic inflammatory response syndrome, COPD and sepsis (see Table 3 ).
T547 3677-3856 Sentence denotes XBJI has been recommended in MERS Diagnosis and Treatment Scheme (Version 2015) and Diagnosis and Treatment Scheme for Human Infection with H7N9 Avian Influenza (Version 1, 2017).
T548 3857-4025 Sentence denotes Clinical research by Wen Long et al. randomly divided 60 severe COVID-19 patients into routine treatment (n = 20), XBJI 50 ml (n = 20), and XBJI 100 ml (n = 20) groups.
T549 4026-4198 Sentence denotes On the basis of conventional treatment, XBJI (50 ml) was injected twice a day for 7 days in the XBJI 50 ml group, or 100 ml twice a day for 7 days in the XBJI 100 ml group.
T550 4199-4335 Sentence denotes After treatment, the white blood cell count (WBC) and lymphocyte count (LYM) of the three groups increased, while CRP and ESR decreased.
T551 4336-4466 Sentence denotes Compared with the routine treatment group, the WBC count in the XBJI 100 ml group after treatment significantly increased (×109/L:
T552 4467-4609 Sentence denotes 7.12 ± 0.55 vs. 5.67 ± 0.51, p < 0.05), and the levels of CRP and ESR in the XBJI 50 ml and 100 ml groups significantly decreased [CRP (mg/L):
T553 4610-4660 Sentence denotes 32.3 ± 4.6, 28.0 ± 6.2 vs. 37.3 ± 5.9; ESR (mm/h):
T554 4661-4714 Sentence denotes 45.9 ± 5.7, 40.5 ± 7.4 vs. 55.3 ± 6.6, all p < 0.05].
T555 4715-4865 Sentence denotes Compared with the XBJI 50 ml group, the increase of WBC, and the decrease of CRP and ESR were more significant in the XBJI 100 ml group [WBC (×109/L):
T556 4866-4906 Sentence denotes 7.12 ± 0.55 vs. 5.82 ± 0.49; CRP (mg/L):
T557 4907-4945 Sentence denotes 28.0 ± 6.2 vs. 32.3 ± 4.6; ESR (mm/h):
T558 4946-4987 Sentence denotes 40.5 ± 7.4 vs. 45.9 ± 5.7, all p < 0.05].
T559 4988-5034 Sentence denotes The APACHE II score of three groups decreased.
T560 5035-5234 Sentence denotes In the XBJI 100 ml group, the APACHE II score after treatment was significantly lower than those in the routine treatment and XBJI 50 ml groups (12.3 ± 1.5 vs. 16.5 ± 1.6, 15.9 ± 1.4, both p < 0.05).
T561 5235-5491 Sentence denotes After treatment, the 2019-nCoV nucleic acid test in the three groups partly turned negative: nine cases in the routine treatment group, eight cases in the XBJI 50 ml group and nine cases in the XBJI 100 ml group, with no significant differences (p > 0.05).
T562 5492-5569 Sentence denotes The conditions of patients in the three groups were improved after treatment.
T563 5570-5793 Sentence denotes Eight cases in the routine treatment group were transformed into common type and one case into critical type; nine cases and 12 cases in the XBJI 50 ml and 100 ml groups, respectively, were transformed into the common type.
T564 5794-5920 Sentence denotes Patients in the XBJI 100 ml group improved more obviously than in the XBJI 50 ml and routine treatment groups (both p < 0.05).
T565 5921-6050 Sentence denotes The XBJI injection can effectively improve the inflammatory markers and prognosis of severe COVID-19 patients (Wen et al., 2020).
T566 6051-6297 Sentence denotes Clinical research by Qi Fei et al. showed that, of 80 patients with severe pneumonia, those receiving a combination of XBJI and conventional treatment exhibited reduced levels of blood LDH, α1-acid glycoprotein (α1-AG) and α1-antitrypsin (α1-AT).
T567 6298-6411 Sentence denotes Body temperature was reduced significantly and secretion of TNF-α, IL-6, IL-8, and other cytokines was inhibited.
T568 6412-6515 Sentence denotes The total treatment efficiency was up to 80%, compared to 67.5% in the control group (Qi et al., 2011).
T569 6516-6825 Sentence denotes An RCT study comprised of 33 centers and 710 patients conducted by Yuanlin Song et al. showed that XBJI in combination with conventional treatment significantly improved the primary endpoint, pneumonia severity index, in patients with severe CAP (the control group vs XBJI Group, 46.33% vs 60.78%, p < 0.001).
T570 6826-7076 Sentence denotes There was also significantly reduced mortality in 28 days (24.65% vs 15.87%, p = 0.006), the duration of mechanical ventilation was shortened (11 vs 16.5 d, p = 0.012) and length of stay in ICU was reduced (12 vs 16 d, p = 0.004) (Song et al., 2019).
T571 7077-7332 Sentence denotes Mingjin Zhu et al. conducted a meta-analysis of 12 studies with a total of 860 patients and showed that XBJI in combination with conventional treatment was superior to the treatment group in improving total response rate in patients with severe pneumonia.
T572 7333-7513 Sentence denotes Infectious indicators (WBC, CRP, CPIS) and inflammatory cytokine (IL-6, IL-8, TNF-α) levels were reduced, and the average length of stay in hospital was reduced (Zhu et al., 2014).
T573 7514-7855 Sentence denotes Wei Zhao et al. studied 56 patients with systemic inflammatory response syndrome (SIRS) and found that after 7 d treatment with XBJI in combination with conventional treatment, body temperature, WBC, and acute physiology and chronic health evaluation II (APACHE-II) score improved more significantly compared to the control group (p < 0.05).
T574 7856-8074 Sentence denotes Expression of CD4+, CD4+/CD8+, CD14+/HLA-DR (human leukocyte antigen-DR) increased significantly, and the combination regulated the SIRS immune state and improved systemic status of the patients (Zhao W. et al., 2014).
T575 8075-8262 Sentence denotes Clinical research found that XBJI in combination with conventional treatment lowered TNF-α, CRP, and other inflammatory indicators in AECOPD patients and had a certain therapeutic effect.
T576 8263-8476 Sentence denotes In patients with accompanying SIRS, the combination significantly improved cough, expectoration, shortness of breath, and other clinical symptoms, and shortened hospital stay (Chen et al., 2011; Zhu et al., 2019).
T577 8477-8862 Sentence denotes Meta-analysis by Chengyu Li et al. included sepsis patients from 16 RCTs (total 1,144 cases), and evidence of moderate intensity showed that XBJI in combination with conventional treatment effectively reduced the mortality rate of sepsis patients over 28 d (934/1144, p < 0.00001), APACHE-II score (792/1144, p < 0.00001) and body temperature (362/1144, p < 0.00001) (Li et al., 2018).
T578 8864-8888 Sentence denotes Usage and Dosage of XBJI
T579 8889-8911 Sentence denotes Intravenous injection.
T580 8912-8955 Sentence denotes 1) Systemic inflammatory response syndrome:
T581 8956-9063 Sentence denotes 50 ml plus 100 ml 0.9% sodium chloride injection for intravenous drip, completed in 30–40 min, twice a day.
T582 9064-9102 Sentence denotes Three times a day for severe patients.
T583 9103-9142 Sentence denotes 2) Multiple-organ dysfunction syndrome:
T584 9143-9251 Sentence denotes 100 ml plus 100 ml 0.9% sodium chloride injection for intravenous drip, completed in 30–40 min, twice a day.
T585 9252-9298 Sentence denotes Three or four times a day for severe patients.
T586 9300-9325 Sentence denotes Adverse Reactions of XBJI
T587 9326-9434 Sentence denotes Allergic reactions: skin flush, rash, itching, palpitations, cyanosis, laryngeal edema, allergic shock, etc.
T588 9435-9534 Sentence denotes Cardiovascular system: palpitations, cyanosis, increase, or decrease of blood pressure, arrhythmia.
T589 9535-9571 Sentence denotes Nervous system: dizziness, headache.
T590 9572-9680 Sentence denotes Respiratory system: difficulty breathing, chest distress, labored breathing, shortness of breath, and cough.
T591 9681-9769 Sentence denotes Digestive system: nausea, vomiting, stomach ache, diarrhea, and abnormal liver function.
T592 9770-9882 Sentence denotes Others: facial edema, conjunctival congestion, abnormal tears, phlebitis, lumbago, backache, and local numbness.
T593 9884-9900 Sentence denotes XBJI Precautions
T594 9901-9981 Sentence denotes 1) Not for use in pregnant women and children under 14 (inclusive) years of age.
T595 9982-10085 Sentence denotes 2) The product must not be mixed with others, and must be used with caution in combination with others.
T596 10086-10193 Sentence denotes When used in combination with other drugs, 50 ml 0.9% sodium chloride injection must be used between doses.
T597 10194-10314 Sentence denotes 3) Allergic history, family allergic history and patient history of medications should be queried before administration.
T598 10315-10417 Sentence denotes 4) During administration, special attention should be given to the initial 30 min of intravenous drip.
T599 10418-10525 Sentence denotes In case of abnormality, the drug should be discontinued immediately and symptomatic treatment administered.
T600 10526-10654 Sentence denotes 5) Monitoring of administration should be enhanced in older patients and in patients receiving TCM injection for the first time.